The HPV vaccine controversy

Virtual Mentor

Volumn 14, Issue 1, 2012, Pages 39-49

  Intlekofer, Karlie A ^a   Cunningham, Michael J ^a   Caplan, Arthur L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; DRUG APPROVAL; ETHICS; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTION; PATIENT ATTITUDE; UNITED STATES; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; CHILD; CONDYLOMATA ACUMINATA; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; FEMALE; HEALTH EDUCATION; HUMANS; MALE; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84877064122     PISSN: 19377010     EISSN: None     Source Type: Journal    
DOI: 10.1001/virtualmentor.2012.14.1.msoc1-1201     Document Type: Article

References (81)

1. Aral SO, Holmes KK. The epidemiology of STIs and their social and behavioral determinants: industrialized and developing countries. Holmes KK, ed. Sexually Transmitted Diseases. 3rd ed. New York: McGraw-Hill; 1999: 53-92.
2. Weinstock H, Berman S, Cates W, Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
3. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-163.
4. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428.
5. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23):2995-3002.
6. Chow LT, Nasseri M, Wolinsky SM, Broker TR. Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol. 1987;61(8):2581-2588.
7. de Villiers EM, Gunst K, Stein H, Scherubl H. Esophageal squamous cell cancer in patients with head and neck cancer: prevalence of human papillomavirus DNA sequences. Int J Cancer. 2004;109(2):253-258.
8. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690-698.
9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
10. Palefsky JM, Holly EA, Gonzales J, Berline J, Ahn DK, Greenspan JS. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res. 1991;51(3):1014-1019.
11. van Beurden M, ten Kate FJ, Smits HL, et al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer. 1995;75(12):2879-2884.
12. Buscema J, Naghashfar Z, Sawada E, Daniel R, Woodruff JD, Shah K. The predominance of human papillomavirus type 16 in vulvar neoplasia. Obstet Gynecol. 1988;71(4):601-606.
13. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006;30(12):1513-1518.
14. Brachman DG, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992;52(17):4832-4836.
15. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-1423.
16. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women’s Health Study. J Infect Dis. 2002;186(4):462-469.
17. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12(6):485-490.
18. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12):2077-2087.
19. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
20. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278-285.
21. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_cid=rr5602a1_e. Accessed September 16, 2011.
22. National Conference of State Legislatures. HPV vaccine; 2011. http://www.ncsl.org/IssuesResearch/Health/HPVVaccineStateLegislation/tabid/14381/Default.aspx#hpvlegis. Accessed October 10, 2011.
23. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796-802.
24. Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002;76(15):7832-7842.
25. Brown DR, Fife KH, Wheeler CM, et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine. 2004;22(21-22):2936-2942.
26. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 viruslike particle candidate vaccines in young healthy women. Vaccine. 2004;22(21-22):2943-2952.
27. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89(24):12180-12184.
28. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185(1):251-257.
29. Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology. 1992;190(1):548-552.
30. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67(4):1936-1944.
31. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
32. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-1765.
33. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
34. Department of Health and Aging, Australian Government. Human papillomavirus (hpv); information about the national HPV Vaccination program funded under the Immunise Australia Program; 2011. http://health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. Accessed December 16, 2011.
35. Joint Committee on Vaccination and Immunisation (JCVI). Statement on human papillomavirus vaccines to protect against cervical cancer; 2008. http://www.parliament.uk/deposits/depositedpapers/2011/DEP20110706.pdf. Accessed September 13, 2011
36. Gardasil approved to prevent anal cancer [news release]. Silver Spring, MD: US Food and Drug Administration; December 22, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm237941.htm. Accessed September 9, 2011
37. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705-719.
38. Centers for Disease Control and Prevention. Reports of health concerns following HPV vaccination. http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html. Accessed October 7, 2011.
39. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(33):1117-1123. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6033a1.htm. Accessed October 1, 2011.
40. Mindel A, Tideman R. HPV transmission-still feeling the way. Lancet. 1999;354(9196):2097-2098.
41. Sonnex C, Strauss S, Gray JJ. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Infect. 1999;75(5):317-319.
42. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226.
43. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-753.
44. Harper DM, Paavonen J. Age for HPV vaccination. Vaccine. 2008;26 Suppl 1:A7-11.
45. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_cid=mm5920a4_e. Accessed September 20, 2011.
46. American Congress of Obstetricians and Gynecologists. Ob Gyns Recommend HPV Vaccination for Young Girls. http://www.acog.org/About_ACOG/News_Room/News_Releases/2010/Ob_Gyns_Recommend_HPV_Vaccination_for_Young_Girls.aspx. Accessed December 16, 2011.
47. Wright TC Jr, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ. Age considerations when vaccinating against HPV. Gynecol Oncol. 2008;109(2 Suppl):S40-S47.
48. Zunzunegui MV, King MC, Coria CF, Charlet J. Male influences on cervical cancer risk. Am J Epidemiol. 1986;123(2):302-307.
49. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol. Nov 2007;107(2 Suppl 1):S24-26.
50. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl. 2000;(205):189-193.
51. FDA approves new indication for gardasil to prevent genital warts in men and boys [news release]. Silver Spring, MD: US Food and Drug Administration; October 16, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187003.htm. Accessed December 15, 2011.
52. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41.
53. Quick CA, Watts SL, Krzyzek RA, Faras AJ. Relationship between condylomata and laryngeal papillomata. Clinical and molecular virological evidence. Ann Otol Rhinol Laryngol. 1980;89(5 Pt 1):467-471.
54. Puranen MH, Yliskoski MH, Saarikoski SV, Syrjanen KJ, Syrjanen SM. Exposure of an infant to cervical human papillomavirus infection of the mother is common. Am J Obstet Gynecol. 1997;176(5):1039-1045.
55. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska S. A possible vertical transmission of human papillomavirus genotypes associated with epidermodysplasia verruciformis. J Invest Dermatol. 1998;111(2):333-336.
56. Rombaldi RL, Serafini EP, Mandelli J, Zimmermann E, Losquiavo KP. Transplacental transmission of human papillomavirus. Virol J. 2008;5:106.
57. Smith EM, Parker MA, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. Evidence for vertical transmission of HPV from mothers to infants. Infect Dis Obstet Gynecol. 2010;2010:326369.
58. Mounts P, Shah KV. Respiratory papillomatosis: etiological relation to genital tract papillomaviruses. Prog Med Virol. 1984;29:90-114.
59. Neiderhuber JE. Taking pride in an important achievement. National Cancer Institute Bulletin. 2006;3(24). http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2006/061306/page3. October 11, 2011.
60. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004;58(7):1405-1413.
61. Focus on the Family. Position statement: human papillomavirus vaccines; 2007. http://www.family.org/sharedassets/correspondence/pdfs/PublicPolicy/Position_Statement-Human_Papillomavirus_Vaccine.pdf. Accessed September 22, 2011.
62. Parker S. The perverse politics of Gardasil. Center for Urban Renewal and Education. http://www.urbancure.org/article.asp?id=3026&tag=. Accessed October 18, 2011.
63. Lo B. HPV vaccine and adolescents’ sexual activity. BMJ. 2006;332(7550):1106-1107.
64. Parker S. Vaccine mandate explains mess of health system. Center for Urban Renewal and Education. http://www.urbancure.org/article.asp?id=3027&tag=. Accessed December 16, 2011.
65. Dempsey AF, Singer D, Clark SJ, Davis MM. Parents’ views on 3 shot-related visits: implications for use of adolescent vaccines like human papillomavirus vaccine. Acad Pediatr. 2009;9(5):348-352.
66. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8(3):188-194.
67. Michele Bachmann says HPV vaccine can cause mental retardation. PolitiFact. September 13, 2011. http://www.politifact.com/truth-ometer/statements/2011/sep/16/michele-bachmann/bachmann-hpv-vaccine-cause-mental-retardation/. Accessed October 11, 2011.
68. Bachmann: Perry’s HPV vaccine order immoral [video]. Today. http://today.msnbc.msn.com/id/26184891/vp/44499076#44499076. Accessed October 11, 2011.
69. Smith B. Bachmann’s vaccine doubts ‘dangerous and irresponsible’. Politico. September 13, 2011. http://www.politico.com/blogs/bensmith/0911/Bachmanns_vaccine_doubts_dangerous_and_irresponsible.html. Accessed October 10, 2011.
70. Burton OM. American Academy of Pediatrics statement on HPV vaccine. Elk Grove Village, IL: American Academy of Pediatrics; September 13, 2011. http://www.aap.org/advocacy/releases/hpv2011.pdf. Accessed September 18, 2011.
71. Morrissey E. Bachmann: Gardasil causes “mental retardation”. Hot Air. September 13, 2011. http://hotair.com/archives/2011/09/13/bachmanngardasil-causes-mental-retardation/. Accessed October 19, 2011.
72. Hafner J. To one Iowa mother, Bachmann decries ‘the ravages’ of HPV vaccine. Des Moines Register. November 14, 2011. http://caucuses.desmoinesregister.com/2011/11/14/to-one-iowa-motherbachmann-decries-the-ravages-of-hpv-vaccine/. Accessed November 15, 2011.
73. Deer B. Schoolboy, 13, dies as measles makes a comeback. April 2, 2006. http://briandeer.com/wakefield/measles-death.htm. Accessed October 19, 2011.
74. Dobson R. Media misled the public over the MMR vaccine, study says. BMJ. 2003;326(7399):1107.
75. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009;19(8):531-538.
76. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117(5):1486-1493.
77. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45(2-3):107-114.
78. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000;9(1):47-50.
79. Fredrickson DD, Davis TC, Arnould CL, et al. Childhood immunization refusal: provider and parent perceptions. Fam Med. 2004;36(6):431-439.
80. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics. 2000;106(5):1097-1102.
81. Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics. 2008;121(4):e836-e843.